靶向急性髓系白血病中的脂质代谢:生物学见解与治疗机会
本综述概述了急性髓系白血病(AML)细胞对脂肪酸和脂质代谢的依赖性,讨论了其与脂肪细胞微环境的功能相互作用,强调了脂质代谢在AML维持和治疗反应中的重要性,并提出了靶向脂质代谢的未解问题及研究 approaches。
要点
- AML细胞的代谢重编程是恶性转化的标志,靶向代谢治疗备受关注。
- 针对线粒体能量产生的代谢治疗因普遍毒性而进展受限,靶向脂质代谢等特化功能是替代策略。
- 脂质代谢在AML维持和治疗反应中的作用日益被认识,需在微环境(尤其脂肪微环境)背景下解读。
核心结论
- 脂质代谢在AML维持和治疗反应中的重要性日益被认识,但需在与其微环境(尤其是脂肪微环境)相互作用的背景下充分解读。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- AML细胞的代谢重编程是恶性转化的标志,靶向治疗潜力备受关注。
- 针对线粒体能量产生的临床代谢靶向治疗在AML中因普遍毒性而进展受限。
- 脂质代谢参与能量储存、氧化应激调节及特定代谢反应所需辅因子可用性等多种特化代谢功能。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic rewiring is a hallmark of malignant transformation in leukemic cells and the potential offered by its therapeutic targeting has garnered significant attention. The development of clinically relevant metabolic targeted therapies in acute myeloid leukemia (AML) has mostly focused on targeting mitochondrial energy production, but progress has been hampered by generalized toxicities. An alternative strategy is to shift the focus from targeting energy production to targeting more specialized metabolic functions, such as energy storage, the regulation of oxidative stress and availability of cofactors needed for the function of specific metabolic reactions. Lipid metabolism plays a role in many of these metabolic functions and its importance in AML maintenance and response to therapy is being increasingly recognized but needs to be adequately interpreted in the context of its interaction with the microenvironment, particularly the adipose niche. In this review, we provide an overview of our current understanding of AML cellular metabolic dependencies on fatty acid and lipid metabolism and discuss their relevance in the context of functional interactions with adipocytes. We highlight unresolved questions about how to best target lipid metabolism and suggest approaches needed to fully understand the interplay between malignant cells and their niche in the context of metabolic dependencies.
引用
- Dembitz V, James SC, Gallipoli P, et al. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 2025. PMID: 40404984. doi:10.1038/s41375-025-02645-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。